BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15094702)

  • 1. Hepatorenal syndrome.
    Cárdenas A; Arroyo V
    Ann Hepatol; 2003; 2(1):23-9. PubMed ID: 15094702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.
    Salerno F; Gerbes A; Ginès P; Wong F; Arroyo V
    Gut; 2007 Sep; 56(9):1310-8. PubMed ID: 17389705
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatorenal syndrome: Current concepts and future perspectives.
    Jung CY; Chang JW
    Clin Mol Hepatol; 2023 Oct; 29(4):891-908. PubMed ID: 37050843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatorenal Syndrome].
    Choi JC; Yoo JJ
    Korean J Gastroenterol; 2023 Nov; 82(5):224-232. PubMed ID: 37997218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of Hepatorenal Syndrome.
    Velez JCQ; Latt N; Rodby RA
    Adv Kidney Dis Health; 2024 Mar; 31(2):87-99. PubMed ID: 38649221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Replacement Therapy in Cirrhosis: A Contemporary Review.
    Pelusio C; Endres P; Neyra JA; Allegretti AS
    Adv Kidney Dis Health; 2024 Mar; 31(2):133-138. PubMed ID: 38649217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepato-Cardio-Renal Syndrome.
    Koratala A; Verbrugge F; Kazory A
    Adv Kidney Dis Health; 2024 Mar; 31(2):127-132. PubMed ID: 38649216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapies in hepatorenal syndrome.
    Achim C; Zgură A; Zgură D; Voiculescu M
    Rom J Intern Med; 2014; 52(4):201-15. PubMed ID: 25726622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of hepatorenal syndrome in patients with cirrhosis.
    Angeli P; Morando F
    Hepat Med; 2010 Jun; 2():87-98. PubMed ID: 24367209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatorenal syndrome: an update.
    Genzini T; Torricelli FC
    Sao Paulo Med J; 2007 Jan; 125(1):50-6. PubMed ID: 17505686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.
    Yeung E; Yong E; Wong F
    MedGenMed; 2004 Dec; 6(4):9. PubMed ID: 15775836
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac Dysfunction in the Pathogenesis of Hepatorenal Syndrome.
    Cailes B; Farouque O; Majumdar A; Koshy AN
    Am J Gastroenterol; 2023 Jan; 118(1):179-180. PubMed ID: 36191281
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatorenal syndrome.
    Ng CK; Chan MH; Tai MH; Lam CW
    Clin Biochem Rev; 2007 Feb; 28(1):11-7. PubMed ID: 17603637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hepatorenal syndrome and treatment-related adverse events.
    Peluso L; Savi M; Coppalini G; Veliaj D; Villari N; Albano G; Petrou S; Pace MC; Fiore M
    Curr Med Res Opin; 2024 Jun; ():1-8. PubMed ID: 38773739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulminant hepatorenal syndrome due to Acetaminophen toxicity: A case report.
    Nekoukar Z; Moghimi M; Zakariaei Z; Fakhar M; Tabaripour R
    Clin Case Rep; 2021 May; 9(5):e04037. PubMed ID: 34084485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.
    Erly B; Carey WD; Kapoor B; McKinney JM; Tam M; Wang W
    Semin Intervent Radiol; 2015 Dec; 32(4):445-54. PubMed ID: 26622108
    [No Abstract]   [Full Text] [Related]  

  • 17. CONFIRMing Hepatorenal Syndrome Management: #NephJC Editorial.
    Willows J; Rydzewska-Rosołowska A; Topf JM; Hiremath S
    Kidney Med; 2022 Jan; 4(1):100352. PubMed ID: 35072039
    [No Abstract]   [Full Text] [Related]  

  • 18. Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome.
    Gonzalez-Garay AG; Serralde-Zúñiga AE; Velasco Hidalgo L; Flores García NC; Aguirre-Salgado MI
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011039. PubMed ID: 38235907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes.
    Moon JJ; Hong SK; Kim YC; Hong SY; Choi Y; Yi NJ; Lee KW; Han SS; Lee H; Kim DK; Kim YS; Yang SH; Suh KS
    PLoS One; 2023; 18(11):e0293844. PubMed ID: 37917773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction models combining zonulin, LPS, and LBP predict acute kidney injury and hepatorenal syndrome-acute kidney injury in cirrhotic patients.
    Lin YH; Kuo NR; Shen HC; Chang YC; Lin R; Liao TL; Yeh HY; Yang YY; Hou MC; Lin HC
    Sci Rep; 2023 Aug; 13(1):13048. PubMed ID: 37567912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.